AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7776391
Drug: tablets
RxNorm normalized name: Mesna Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: 7776391
Drug: single-dose sachets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single-dose sachets of antibiotic powder
Trial: 2098143
Drug: Cefotaxime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (1 g intravenous infusion one hour before operation)
Trial: 2098143
Drug: Ceftriaxone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (1 g intravenous infusion one hour before operation)
Trial: 2098143
Drug: Control (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (without antibiotics)
Trial: 6253099
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) alone: 4500 rads in 5-6 weeks to primary tumor and regional lymph nodes, and 3500 rads in 2 1/2 weeks to brain as prophylaxis.
Trial: 6253099
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) + chemotherapy (CT) with cyclophosphamide (500 mg/m2), Adriamycin (50 mg/m2), and DTIC (250 mg/m2) every 3 weeks for two cycles before RT and seven cycles post-RT.
Trial: 30429927
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg IV ketamine
Trial: 23864538
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg purified (-)-epicatechin perfused into an isolated jejunal segment
Trial: 20299396
Drug: Weekly sunbed
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly sunbed use
Trial: 19127801
Drug: Cefper injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefper injection (1.5 g cefoperazone and sulbactam)
Trial: 19127801
Drug: Sulperazon injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulperazon injection (1.5 g cefoperazone and sulbactam)
Trial: 15889524
Drug: Shenmai Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenmai Injection plus routine treatment
Trial: 10498560
Drug: Azithromycin (1.0-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1.0-g dose)
Trial: 8556221
Drug: Diarex Lactab
RxNorm normalized name: Diaprex
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diarex Lactab (test preparation)
Trial: 8556221
Drug: Imodium capsules
RxNorm normalized name: loperamide Oral Capsule [Imodium]
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imodium capsules (reference preparation)
Trial: 6109585
Drug: Bevantolol 75
RxNorm normalized name: bevantolol
DrugBank: Bevantolol (DB01295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevantolol 75 mg
Trial: 6109585
Drug: Bevantolol 150
RxNorm normalized name: bevantolol
DrugBank: Bevantolol (DB01295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevantolol 150 mg
Trial: 24989721
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral antioxidants in the form of multivitamins and minerals (amino acid chelated)
Trial: 19302638
Drug: Low-Dose Infusion
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-Dose Infusion (LDI)
Trial: 19302638
Drug: High-Dose Epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dose Epidural (Control)
Trial: 11216925
Drug: Protease inhibitor-resistant
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor-resistant isolates
Trial: 11216925
Drug: Protease inhibitor-sensitive
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor-sensitive isolates
Trial: 7861712
Drug: Intermittent calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent calcitriol therapy (oral or intraperitoneal doses) for 12 months
Trial: 7861712
Drug: Intermittent calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent calcitriol therapy
Trial: 181692
Drug: Caffeine (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (1,000 mg daily)
Trial: 181692
Drug: Bromocriptine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (40 mg daily)
Trial: 31297965
Drug: bexagliflozin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bexagliflozin (20 mg)
Trial: 28550977
Drug: Ezetimibe (10mg/day)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe (10mg/day) and Simvastatin (40mg/day) combination therapy
Trial: 24517252
Drug: Danoprevir/r 200/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danoprevir/r 200/100 mg plus P/R for 24 weeks (Arm A)
Trial: 24517252
Drug: Danoprevir/r 100/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danoprevir/r 100/100 mg plus P/R for 24 weeks (Arm B)
Trial: 24517252
Drug: Danoprevir/r 50/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danoprevir/r 50/100 mg plus P/R for 24 weeks (Arm C)
Trial: 24517252
Drug: Danoprevir/r 100/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danoprevir/r 100/100 mg plus P/R for 12 or 24 weeks (Arm D)
Trial: 20889211
Drug: Low-dose peginterferon-α2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose peginterferon-α2a 90 μg/week
Trial: 12616178
Drug: Behavioral graded
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral graded activity and problem-solving therapy (GAPS)
Trial: 8694309
Drug: 10 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL/kg crystalloid volume
Trial: 8694309
Drug: 20 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL/kg crystalloid volume
Trial: 8694309
Drug: 30 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL/kg crystalloid volume
Trial: 3926848
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with intraaortic balloon pumping and intravenous nitroglycerin for 4 to 5 days
Trial: 3926848
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with intraaortic balloon pumping and intravenous nitroglycerin
Trial: 28066111
Drug: Low-cost brand
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-cost brand (LCB) amlodipine 5 mg once daily for 6 weeks
Trial: 28066111
Drug: Innovator brand
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Innovator brand (IB) amlodipine 5 mg once daily for 6 weeks
Trial: 21510459
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone at a dose of 4 microg/Kg/day
Trial: 18951261
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol Diskus 100/50 mcg BID (FSC)
Trial: 18951261
Drug: Salmeterol (SAL)
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Salmeterol (SAL) 50 mcg BID
Trial: 7884423
Drug: Complex therapies
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex therapies evaluated in IRS‐III
Trial: 7181476
Drug: Ceforanide (two-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceforanide (two-dose regimen)
Trial: 7181476
Drug: Cephalothin (six-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalothin (six-dose regimen)
Trial: 30665464
Drug: Low-dose acetylsalicylic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acetylsalicylic acid (ASA)
Trial: 23171536
Drug: cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cognitive-behavioral therapy (CBT)
Trial: 19903773
Drug: Classrooms cleaned
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classrooms cleaned daily with a quaternary ammonium wipe
Trial: 19903773
Drug: Control classrooms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control classrooms (not cleaned daily)
Trial: 9807603
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 16 ml/kg plus intravenous ephedrine boluses (0.1 mg/kg)
Trial: 9807603
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 8 ml/kg plus intramuscular depot ephedrine (0.5 mg/kg)
Trial: 9807603
Drug: Haemaccel 8
RxNorm normalized name: Haemaccel
DrugBank: Polygeline (DB15879)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemaccel 8 ml/kg plus metaraminol infusion
Trial: 2566248
Drug: Clobazam 40
RxNorm normalized name: Clobazam
DrugBank: Clobazam (DB00349)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clobazam 40 mg
Trial: 263938
Drug: Dextroamphetamine sulfate
RxNorm normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine sulfate 5 mg/70 kg
Trial: 263938
Drug: Dextroamphetamine sulfate
RxNorm normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine sulfate 10 mg/70 kg
Trial: 263938
Drug: Dextroamphetamine sulfate
RxNorm normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine sulfate 15 mg/70 kg
Trial: 263938
Drug: Dextroamphetamine sulfate
RxNorm normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine sulfate 0 mg/70 kg (placebo)
Trial: 28352657
Drug: Erlotinib (EGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (EGFR inhibitor)
Trial: 28352657
Drug: Dasatinib (Src
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (Src inhibitor)
Trial: 28352657
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of erlotinib and dasatinib
Trial: 26475403
Drug: 200 ng/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ng/mL cutoff
Trial: 26475403
Drug: 500 ng/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ng/mL cutoff
Trial: 25098502
Drug: Daily non‐smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily non‐smoking related text messages (control condition)
Trial: 10971315
Drug: ORAL +
RxNorm normalized name: Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORAL + C
Trial: 3775141
Drug: Stress management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress management program for treatment of hypertension (10 weeks duration)
Trial: 19104769
Drug: Salsalate (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salsalate (3 g/day, n = 28)
Trial: 17001068
Drug: Bortezomib 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.3 mg/m² administered on days 1, 4, 8, and 11 of a 21-day cycle, for up to 17 cycles.
Trial: 14557435
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg twice daily for 3 months, then 1000 mg twice daily for 3 months)
Trial: 14557435
Drug: Ethinyl estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinyl estradiol (35 micro g)‐cyproterone acetate (2 mg) oral contraceptive pills
Trial: 10389531
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg aspirin 1 dd
Trial: 8965185
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion (Group 1, n = 10)
Trial: 8965185
Drug: Placebo bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bolus infusions (Group 2, n = 8)
Trial: 6407812
Drug: i.v. verapamil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. verapamil, 5‐10 mg/h for two days
Trial: 31478125
Drug: High monocyte
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High monocyte count (HMC) group (monocytes ≥ 0.53 × 10^9/L)
Trial: 31478125
Drug: Low monocyte
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low monocyte count (LMC) group (monocytes < 0.53 × 10^9/L)
Trial: 24530146
Drug: Self-administered microneedle
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered microneedle patches
Trial: 24530146
Drug: Microneedle patches
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedle patches (snap device)
Trial: 24530146
Drug: Placebo microneedle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo microneedle patches
Trial: 12011795
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (5000 lux from 6-8 a.m.) and imipramine 150 mg/day
Trial: 12011795
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (5000 lux from 6-8 a.m.) and imipramine-like placebo
Trial: 12011795
Drug: Dim red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim red light (500 lux from 6-8 a.m.) and imipramine 150 mg/day
Trial: 30121697
Drug: Bromocriptine 2.5
RxNorm normalized name: bromocriptine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 2.5 mg for 1 week (n=10)
Trial: 30121697
Drug: Bromocriptine 5
RxNorm normalized name: bromocriptine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 5 mg for 2 weeks followed by 2.5 mg for 6 weeks (n=14)
Trial: 21767413
Drug: Individualized therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized therapy recommended by clinicians
Trial: 1581948
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine integrated with EPI
Trial: 28701365
Drug: McKenzie Method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: McKenzie Method of Mechanical Diagnosis and Therapy (MDT)
Trial: 20842406
Drug: Free base
RxNorm normalized name: K201 free base
DrugBank: K201 free base (DB02929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free base tablet formulation (180 mg)
Trial: 20842406
Drug: Bisphosphate salt
RxNorm normalized name: glucose 1,6-bisphosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphate salt capsule formulation (240 mg; 183 mg free base equivalent)
Trial: 20842406
Drug: Bisphosphate salt
RxNorm normalized name: glucose 1,6-bisphosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphate salt capsule formulation (200 mg) administered 3 times a week
Trial: 20836725
Drug: PF-592379 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-592379 (200 mg oral dose)
Trial: 1964728
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of beta-carotene daily for four weeks
Trial: 1964728
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg of beta-carotene daily for four weeks
Trial: 26516
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg mequitazine daily for 14 days
Trial: 26516
Drug: 24 mg
RxNorm normalized name: uracil 224 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg brompheniramine daily for 14 days
Trial: 31162128
Drug: Telemedicine intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telemedicine intervention via SMS text messages (every other week or weekly)
Trial: 25841624
Drug: Charged Particle
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Charged Particle Therapy (CPT)
Trial: 25841624
Drug: Iodine-125 Plaque
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine-125 Plaque Therapy
Trial: 17309740
Drug: absence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: absence of an irrigating solution (control)
Trial: 9692126
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms of salbutamol inhaled from the MDPI
Trial: 9692126
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms of salbutamol inhaled from the pMDI + S
Trial: 8147091
Drug: R32Tox‐A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R32Tox‐A vaccine
Trial: 28145964
Drug: Laparoscopic-assisted rectus
RxNorm normalized name: Sus scrofa rectum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic-assisted rectus sheath block (LRSB) with 10 mL of 0.25% levobupivacaine at 4 sites after umbilical wound closure
Trial: 24601127
Drug: VUS-guided peripheral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VUS-guided peripheral intravenous catheter insertion
Trial: 16187009
Drug: Nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 mg daily for 4 weeks
Trial: 16187009
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg daily for 4 weeks
Trial: 12576946
Drug: MAB-T88 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAB-T88 (300 mg intravenous infusion over 30 mins)
Trial: 10593636
Drug: High baseline
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High baseline daily stress
Trial: 9363264
Drug: Quinfamide at
RxNorm normalized name: quinfamide
DrugBank: Quinfamide (DB12780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinfamide at doses of 4.3 mg/kg b.i.d. in children and 100 mg t.i.d. in adults for one day
Trial: 9363264
Drug: Etiamide at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etiamide at doses of 200 mg t.i.d. in children and 500 mg b.i.d. in adults for three days
Trial: 6445816
Drug: 1.5 percent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 percent solution of erythromycin
Trial: 6445816
Drug: 1.5 percent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 percent solution of erythromycin (continued therapy)
Trial: 28319947
Drug: Capsaicin (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin (0.75 µg)
Trial: 16426289
Drug: Cream product
RxNorm normalized name: Oral Cream Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream product preserved with diazolidinyl urea at varying concentrations
Trial: 15296364
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (whirlpool, ultrasound, first MPJ mobilizations, calf and hamstring stretching, marble pick-up exercise, cold packs, and electrical stimulation)
Trial: 24164587
Drug: Topical antibiotic
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antibiotic prophylaxis
Trial: 24164587
Drug: Standard systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard systemic antibiotic prophylaxis
Trial: 15641864
Drug: Risperidone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (0.5 to 8 mg daily for 8 weeks)
Trial: 11504166
Drug: Carvedilol plus
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol plus ACE inhibitor (enalapril)
Trial: 11504166
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor alone
Trial: 9785089
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of macrophages prepared from a blood unit
Trial: 7963169
Drug: Glutamine-supplemented parenteral
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine-supplemented parenteral nutrition
Trial: 15327343
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (3 blocks of single sessions over one year, 8 to 10 sessions)
Trial: 7967359
Drug: Desferrioxamine (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desferrioxamine (subcutaneous infusion 50 mg/kg/12 hr)
Trial: 7967359
Drug: Desferrioxamine (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desferrioxamine (intravenous infusion 50 mg/kg/6 hr or 100 mg/kg/24 hr)
Trial: 7967359
Drug: Desferrioxamine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desferrioxamine (both subcutaneous and intravenous)
Trial: 31622733
Drug: Durvalumab, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab, 10 mg/kg intravenously every 2 weeks for up to 12 months
Trial: 21969495
Drug: P-CAP (perifosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-CAP (perifosine 50 mg orally once daily, days 1 to 21 and CAP 825 mg/m2 orally twice daily, days 1 to 14)